AAV-Associated Complement Activation in the Clinical Trial Setting
Time: 9:15 am
day: Day Two
Details:
- Review of the complement system and pathophysiology of thrombotic microangiopathy (TMA) – broadening our perspective on organ systems at risk
- Exploring episodes of complement-mediated TMA seen in AAV clinical trials
- Mechanistic hypotheses regarding TMA risk in different gene therapy settings
- Practical considerations around TMA surveillance, prophylaxis and management
Speakers:
